125 related articles for article (PubMed ID: 38819794)
1. Metabolomics analysis reveals characteristic metabolites in different levels of oxaliplatin-induced neurotoxicity.
Hua Y; Wang R; Liu Y; Liu Q; Qi X; Ding Y; Lv J
J Sep Sci; 2024 Jun; 47(11):e2400164. PubMed ID: 38819794
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
[TBL] [Abstract][Full Text] [Related]
3. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity.
Alberti P; Canta A; Chiorazzi A; Fumagalli G; Meregalli C; Monza L; Pozzi E; Ballarini E; Rodriguez-Menendez V; Oggioni N; Sancini G; Marmiroli P; Cavaletti G
Neuropharmacology; 2020 Mar; 164():107905. PubMed ID: 31811874
[TBL] [Abstract][Full Text] [Related]
4. Platinum accumulation in oxaliplatin-induced peripheral neuropathy.
Wei G; Gu Z; Gu J; Yu J; Huang X; Qin F; Li L; Ding R; Huo J
J Peripher Nerv Syst; 2021 Mar; 26(1):35-42. PubMed ID: 33462873
[TBL] [Abstract][Full Text] [Related]
5. Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity.
Nepal MR; Taheri H; Li Y; Talebi Z; Uddin ME; Jin Y; DiGiacomo DF; Gibson AA; Lustberg MB; Hu S; Sparreboom A
Cancer Res Commun; 2022 Nov; 2(11):1334-1343. PubMed ID: 36506732
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
[TBL] [Abstract][Full Text] [Related]
7. Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development.
Yang Y; Zhao B; Gao X; Sun J; Ye J; Li J; Cao P
J Exp Clin Cancer Res; 2021 Oct; 40(1):331. PubMed ID: 34686205
[TBL] [Abstract][Full Text] [Related]
8. Differential protein expression profiling by iTRAQ-2D-LC-MS/MS of rats treated with oxaliplatin.
Sun X; Lv Y; Wang J; Cheng H; Huang J; Du Y; Dong J
J Cell Biochem; 2019 Oct; 120(10):18128-18141. PubMed ID: 31237037
[TBL] [Abstract][Full Text] [Related]
9. Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy.
Chen SJ; Chen LH; Yeh YM; Lin CK; Lin PC; Huang HW; Shen MR; Lin BW; Lee JC; Lee CC; Lee YF; Chiang HC; Chang JY
Theranostics; 2021; 11(10):4672-4687. PubMed ID: 33754020
[No Abstract] [Full Text] [Related]
10. Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients - a randomized controlled trial. (OxaNeuro).
Gehr NL; Karlsson P; Timm S; Christensen S; Hvid CA; Peric J; Hansen TF; Lauritzen L; Finnerup NB; Ventzel L
BMC Cancer; 2024 Feb; 24(1):168. PubMed ID: 38308227
[TBL] [Abstract][Full Text] [Related]
11. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.
Balayssac D; Ferrier J; Pereira B; Gillet B; Pétorin C; Vein J; Libert F; Eschalier A; Pezet D
BMJ Open; 2015 Apr; 5(4):e007479. PubMed ID: 25833669
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-toxicodynamic Modeling to Elucidate the Involvement of Dorsal Root Ganglion Neuron in Oxaliplatin-induced Peripheral Neuropathy.
Tsukushi Y; Kobuchi S; Ito Y; Sakaeda T
Anticancer Res; 2024 Feb; 44(2):575-584. PubMed ID: 38307592
[TBL] [Abstract][Full Text] [Related]
13. Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study.
Oh PJ; Lee JR; Kim SK; Kim JH
Eur J Oncol Nurs; 2020 Feb; 44():101676. PubMed ID: 31751847
[TBL] [Abstract][Full Text] [Related]
14. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy.
Kim SH; Choi MK; Park NY; Hyun JW; Lee MY; Kim HJ; Jung SK; Cha Y
Sci Rep; 2020 May; 10(1):7995. PubMed ID: 32409710
[TBL] [Abstract][Full Text] [Related]
15. Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin.
Yildirim N; Cengiz M
Support Care Cancer; 2020 Oct; 28(10):4781-4788. PubMed ID: 31974772
[TBL] [Abstract][Full Text] [Related]
16. Laser acupuncture attenuates oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: a pilot prospective cohort study.
Hsieh YL; Chou LW; Hong SF; Chang FC; Tseng SW; Huang CC; Yang CH; Yang CC; Chiu WF
Acupunct Med; 2016 Oct; 34(5):398-405. PubMed ID: 27613370
[TBL] [Abstract][Full Text] [Related]
17. Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2).
Miura Y; Ando M; Yamazaki K; Hironaka S; Boku N; Muro K; Hyodo I
Support Care Cancer; 2021 Jul; 29(7):3715-3723. PubMed ID: 33200233
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of traditional plant-based medicines for preventing chronic oxaliplatin-induced peripheral neurotoxicity in patients with colorectal cancer: A systematic review and meta-analysis with core herb contribution.
Han J; Lai H; Li W; Liao H; Xiao C; Li X; You F; Guo J
J Ethnopharmacol; 2024 May; 326():117735. PubMed ID: 38211824
[TBL] [Abstract][Full Text] [Related]
19. Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies.
Miyamoto T; Domoto R; Sekiguchi F; Kamaguchi R; Nishimura R; Matsuno M; Tsubota M; Fujitani M; Hatanaka S; Koizumi Y; Wang D; Nishibori M; Kawabata A
J Pharmacol Sci; 2022 Mar; 148(3):315-325. PubMed ID: 35177211
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment.
Kang L; Tian Y; Xu S; Chen H
J Neurol; 2021 Sep; 268(9):3269-3282. PubMed ID: 32474658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
